A new study published in NAR Molecular Medicine by researchers at the Norwegian University of Science and Technology (NTNU) has revealed a potentially serious side effect of a common class of anti-inflammatory medications. Janus kinase inhibitors, or JAKs, are widely prescribed for conditions such as rheumatoid arthritis, but the study finds they can suppress an important immune signalling pathway that normally helps protect healthy cells from viral attacks.
“We have found a surprising and potentially serious side effect of a class of anti-inflammatory drugs. They can help viruses spread more easily in the body,” said Denis Kainov, a professor at NTNU’s Department of Clinical and Molecular Medicine.
Among the viruses the researchers say may more readily infect cells with the help of these drugs are Rift Valley fever virus, influenza A, adenovirus and SARS-CoV-2, the virus that causes COVID-19. The team, including PhD research fellow Erlend Ravlo and researcher Aleksandr Ianevski, used advanced virology methods, gene expression analysis and organoid technology to examine the effects in cells from the lungs, eyes and brain.
“In particular, the drugs suppress an important immune signalling pathway that helps protect healthy cells from viral attacks,” Ravlo said. The scientists found that JAK inhibitors, including the drug baricitinib, can reduce the activity of genes that play a crucial role in the body's response to viral infections.
“Although JAK inhibitors are effective in the treatment of inflammation, this shows that they can pose a hidden risk for patients who have latent or active viral infections,” Ravlo added. The researchers recommend further studies to understand how the drugs can be used optimally, especially during virus outbreaks or pandemics.
